Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Matthew Rioth

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED

    Collapse Biography 
    Collapse awards and honors
    2016 - 2017Young Investigator Award, Conquer Cancer Foundation of ASCO

    Collapse Overview 
    Collapse overview
    Dr. Rioth received his undergraduate degree from Harvard University. He completed medical school, residency and oncology fellowship at Vanderbilt University as well as a graduate degree in biomedical informatics. He was awarded an American Society of Clinical Oncology 2016 Young Investigator Award, and joined the faculty of the University of Colorado in 2016. Working with scientists in both biomedical informatics and in oncology, Dr. Rioth’s research focuses on the identification of new cancer biomarkers and accelerating the translation of these scientific advances into the clinic. Cancer patients are increasingly benefiting from treatments that target specific genetic weaknesses in their tumors. To discover these targets, genetic sequencing of large panels of genes produces large quantities of genetic information. Unfortunately, the clinical significance of much of this information is unclear, mostly because there haven’t been enough similar changes observed to make strong conclusions, and prediction technologies are in their infancy. However, it may be possible to discover new significant weaknesses by looking at the clinical information of large populations of patients. With more clinical data available within electronic health records, the possibility of discovering new significant relationships now exists.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rioth MJ, Thota R, Staggs DB, Johnson DB, Warner JL. Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling. J Am Med Inform Assoc. 2016 Jul; 23(4):773-6. PMID: 27026612.
      View in: PubMed
    2. Warner JL, Rioth MJ, Mandl KD, Mandel JC, Kreda DA, Kohane IS, Carbone D, Oreto R, Wang L, Zhu S, Yao H, Alterovitz G. SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care. J Am Med Inform Assoc. 2016 Jul; 23(4):701-10. PMID: 27018265.
      View in: PubMed
    3. Rioth MJ, Staggs DB, Hackett L, Haberman E, Tod M, Levy M, Warner J. Implementing and Improving Automated Electronic Tumor Molecular Profiling. J Oncol Pract. 2016 Mar; 12(3):e332-7. PMID: 26813927.
      View in: PubMed
    4. Rioth MJ, Warner J, Savani BN, Jagasia M. Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology. Bone Marrow Transplant. 2016 Jan; 51(1):34-40. PMID: 26367235.
      View in: PubMed
    5. Rioth MJ, Osterman TJ, Warner JL. Advances in website information resources to aid in clinical practice. Am Soc Clin Oncol Educ Book. 2015; e608-15. PMID: 25993230.
      View in: PubMed
    6. Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol. 2014 Dec; 15(4):658-69. PMID: 25096781.
      View in: PubMed
    7. Ryeom S, Baek KH, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, Yoon SS, McKeon F. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell. 2008 May; 13(5):420-31. PMID: 18455125.
      View in: PubMed
    8. Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-Mckay P, Ryan A, Folkman J, Ryeom S, Heymach J. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther. 2008 Feb; 7(2):418-24. PMID: 18245671.
      View in: PubMed
    9. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K. TORC1 is essential for NF1-associated malignancies. Curr Biol. 2008 Jan 08; 18(1):56-62. PMID: 18164202.
      View in: PubMed
    10. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A. 2006 Oct 31; 103(44):16266-71. PMID: 17056717.
      View in: PubMed
    Rioth's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)